MabVax Therapeutics to Present at the BIO CEO & Investor Conference

SAN DIEGO, Feb. 10, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage immuno-oncology drug development company, announced today that it will be presenting at the BIO CEO & Investor Conference being held February 13-14, 2017 at the Waldorf Astoria Hotel in New York.

Event: 2017 BIO CEO & Investor Conference – webcast available
Location: Waldorf Astoria Hotel, New York
Date: Monday, February 13, 2017 
Time: 3:30 PM (ET) in the Duke of Windsor Room

MabVax Therapeutics President and CEO David Hansen will deliver the Company's presentation focused on the significance of recent interim clinical data and the company's development strategy going forward for its phase 1 clinical trials of MVT-5873 for the treatment of pancreatic cancer, MVT-2163 as a companion diagnostic, and MVT-1075 as the radioimmunotherapy product candidate.  Mr. Hansen will also be available for one-on-one meetings. To arrange a meeting with management, please contact either Gregory Hanson at gregoryhanson@mabvax.com or visit the BIO CEO One-on-One Partnering webpage to schedule a one-on-one directly. 

About MabVax

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company's proprietary vaccines.  MabVax's HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center.  The antigen the antibody targets is expressed on more than 90% of pancreatic cancers, making the antibody potentially broadly applicable to most patients suffering from this type of cancer.  MabVax is headquartered in San Diego.  Additional information is available at www.mabvax.com.

Forward Looking Statements:

This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's clinical trials of MVT-1075, MVT-5873, and MVT-2163. We have no assurance that any of the three product candidates will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2015, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.

MabVax Contacts:

Investor Relations:
Gregory Hanson, CFO
858-500-8457

David Hansen, President and CEO
858-500-8455

SOURCE MabVax Therapeutics Holdings, Inc.